Noubar Afeyan

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $25 billion in aggregate value. To date, Flagship has attracted $2.4 billion of aggregate capital commitments, of which over $1.3 billion has been deployed toward the founding and growth of its pioneering companies alongside $8.3 billion of follow-on investments from other institutions. The current Flagship ecosystem includes public companies such as Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Rubius Therapeutics (NASDAQ:RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS), as well as private companies such as Kaleido Biosciences, Indigo Agriculture, CiBO Technologies, and Moderna Therapeutics. To learn more about Flagship Pioneering, please visit our website: www.FlagshipPioneering.com.